Welcome to our dedicated page for Ideaya Biosciences news (Ticker: IDYA), a resource for investors and traders seeking the latest updates and insights on Ideaya Biosciences stock.
IDEAYA Biosciences, Inc. (NASDAQ: IDYA) is a precision medicine oncology company whose news flow is driven by clinical trial milestones, regulatory interactions, strategic collaborations, and corporate updates. The company regularly issues press releases detailing progress across a deep pipeline of targeted small molecules and antibody-drug conjugates (ADCs) for molecularly defined solid tumors.
News related to IDYA often highlights developments in its lead program darovasertib, an oral protein kinase C inhibitor in clinical trials for uveal melanoma. Updates include enrollment milestones, progression-free survival and overall survival data from trials such as OptimUM-01 and OptimUM-02 in metastatic uveal melanoma, and neoadjuvant data from OptimUM-09 and the Phase 3 OptimUM-10 trial in primary uveal melanoma. IDEAYA also reports on regulatory designations for darovasertib and its collaboration with Servier for rights outside the United States.
Investors following IDEAYA news will see frequent announcements on its broader pipeline, including IDE397 for MTAP-deleted urothelial cancer and NSCLC, IDE849 for small cell lung cancer and neuroendocrine carcinomas, IDE161 as a PARG inhibitor for ADC combinations, IDE034 as a bispecific B7H3/PTK7 TOP1 ADC, IDE574 as a KAT6/7 dual inhibitor, and IDE892 as a PRMT5 inhibitor. Press releases cover IND submissions and clearances, Phase 1 and Phase 2 data readouts, and plans for upcoming medical conference presentations.
IDYA news also includes financial results, cash runway commentary, licensing transactions such as the Servier darovasertib agreement, and governance or compensation updates reported via SEC filings and corporate press releases. Tracking this news stream provides insight into IDEAYA’s clinical progress, partnering activity, and evolving precision oncology strategy.
IDEAYA Biosciences (NASDAQ: IDYA) announced the appointment of Dr. Susan Kelley to its Board of Directors, enhancing its leadership in oncology research. Dr. Kelley brings over 25 years of experience, notably as Chief Medical Officer at the Multiple Myeloma Research Consortium, and previous roles at Bayer and Bristol-Myers Squibb. Her expertise will support the advancement of IDEAYA's clinical programs, including the Phase 1 IDE397 and potential Phase 2 expansion for IDE196. This strategic addition aims to strengthen IDEAYA's pipeline of precision medicine oncology therapies.
IDEAYA Biosciences (NASDAQ: IDYA) announced the successful IND application for IDE397, a MAT2A inhibitor, enabling a Phase 1 clinical trial for cancer patients with MTAP deletion, found in 15% of solid tumors. The trial is set to begin in Q1 2021. Additionally, Matthew Maurer, M.D., has joined as Vice President, bringing over 15 years of oncology experience. His expertise will support the advancement of IDE397 and the company's PARG program. The announcement highlights IDEAYA's commitment to targeted therapeutics in precision medicine and the ongoing development of its synthetic lethality pipeline.
IDEAYA Biosciences (Nasdaq: IDYA) announced its participation in two key investor relations events in February 2021. The Guggenheim Healthcare Talks 2021 Oncology Day will include a fireside chat with analyst Michael Schmidt on February 12 at 12:00 pm ET, while the LifeSci Partners Precision Oncology Event is scheduled for February 17 at 2:00 pm ET. Live audio webcasts of both presentations will be accessible on the IDEAYA website and will be available for replay for 30 days.
IDEAYA Biosciences (Nasdaq: IDYA) has partnered with Spelman College to develop the next generation of female African American leaders in biotechnology. This initiative includes mentorship, internships, and scholarships for selected students. Participants will receive industry-focused education and career guidance. IDEAYA aims to support these students financially and professionally, contributing to the future of oncology-focused precision medicine, particularly in addressing health disparities among people of African descent.
IDEAYA Biosciences (Nasdaq:IDYA) has submitted an Investigational New Drug (IND) application to the FDA for IDE397, a MAT2A inhibitor aimed at treating solid tumors with MTAP deletion. This marks a significant milestone in IDEAYA's research pipeline focused on synthetic lethality therapies. Approximately 15% of solid tumors have the MTAP deletion, representing a potential patient population for IDE397. IDEAYA will share further details at the 39th Annual J.P. Morgan Healthcare Conference, including preclinical data showing tumor regressions and proposed clinical plans.
IDEAYA Biosciences (Nasdaq:IDYA) announced the First-Patient-In (FPI) in a Phase 1 combination study of IDE196 and crizotinib for metastatic uveal melanoma (MUM). This collaboration with Pfizer aims to evaluate the effectiveness of IDE196 alongside the cMET inhibitor crizotinib. IDEAYA's translational research identified cMET as a potential combination agent. The company plans to present preclinical data supporting the IDE196/crizotinib therapy in H1 2021, addressing a significant unmet medical need in treating MUM.
IDEAYA Biosciences (Nasdaq:IDYA) announced participation in key investor and scientific events in January 2021. Events include the JP Morgan 39th Annual Healthcare Conference on January 13 and the HC Wainwright Bioconnect on January 14, both virtual presentations. Additionally, IDEAYA will present at the PARP & DDR Inhibitors Summit on January 28, focusing on innovative cancer treatments. Webcasts will be available on their website, with replays accessible for 30 days. IDEAYA specializes in precision oncology, targeting therapies based on molecular diagnostics.
IDEAYA Biosciences (NASDAQ: IDYA), an oncology-focused precision medicine company, announced its selection for inclusion in the NASDAQ Biotechnology Index, effective prior to market open on December 21, 2020. This index tracks biotechnology and pharmaceutical securities on the NASDAQ and is recognized for its stringent criteria, including market value and share volume requirements. The inclusion may enhance IDEAYA's visibility and credibility in the market, potentially benefiting its stock performance.
IDEAYA Biosciences, Inc. (Nasdaq: IDYA) reported its Q3 2020 financial results, highlighting a cash position of $288.8 million, up from $100.5 million at the end of 2019. With collaboration revenue of $9.0 million, the company advances its synthetic lethality pipeline, including partnerships with GSK. Key updates include the IDE397 program targeting MAT2A, ongoing clinical trials for IDE196 in metastatic uveal melanoma, and strategic collaborations with Broad Institute and UCSD. The net loss for Q3 2020 was $4.9 million, significantly reduced from $11.0 million a year prior.
IDEAYA Biosciences (Nasdaq:IDYA), a precision medicine company focused on oncology, announced its participation in upcoming investor events. The company will present at the Stifel 2020 Healthcare Conference on November 16, 2020, at 1:00 pm PT, and hold a fireside chat at the Jefferies London Healthcare Conference on November 18, 2020, at 9:35 am PT. Live webcasts and subsequent replays will be available on IDEAYA's investor calendar page.
IDEAYA aims to develop targeted therapeutics using molecular diagnostics and biomarkers.